A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

Sunil K Joshi; Setareh Sharzehi; Janét Pittsenbarger; Daniel Bottomly; Cristina E Tognon; Shannon K McWeeney; Brian J Druker; Elie Traer

doi:10.1002/ajh.26174

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

Am J Hematol. 2021 Jul 1;96(7):E226-E229. doi: 10.1002/ajh.26174. Epub 2021 Apr 13.

Authors

Sunil K Joshi^{1

2

3}, Setareh Sharzehi^{1

3

4}, Janét Pittsenbarger^{1

3}, Daniel Bottomly^{1

5}, Cristina E Tognon^{1

3}, Shannon K McWeeney^{1

5}, Brian J Druker^{1

3

4}, Elie Traer^{1

3

4}

Affiliations

¹ Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
² Department of Physiology & Pharmacology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
³ Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
⁴ Department of Cell, Development, & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
⁵ Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Aniline Compounds / pharmacology*
Cell Line, Tumor
Drug Resistance, Neoplasm*
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Models, Molecular
Mutation / drug effects
Protein Kinase Inhibitors / pharmacology*
Pyrazines / pharmacology*
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Aniline Compounds
Protein Kinase Inhibitors
Pyrazines
gilteritinib
FLT3 protein, human
fms-Like Tyrosine Kinase 3

Publication types

MeSH terms

Substances

Grants and funding